Due to COVID-19 we are now offering TeleHealth Office Visits via video or phone call. Learn More >
We have prepared for the Coronavirus (COVID-19). We have updated policies to protect our patients and staff. Learn more.

A Promising New Drug for Lung Cancer

Scientists have tested and verified a new drug that can help treat early-stage lung cancer. The FDA-approved drug known as Osimertinib was tested on non-small cell lung cancer patients, and about 90% of them survived after two years of treatment without any recurrence.

Non-small cell lung cancer is most common in women and people who don’t smoke.

According to the study, when patients with early-stage non-small cell lung cancer with EGFR gene mutations are treated with Osimertinib after surgery, their disease-free survival rates improve significantly. The targeted therapy drug demonstrated plenty of benefits in the trial and was recommended for use immediately.

The data provided for disease-free survival was profound. Initially, the team was hoping that Osimertinib would become an alternative to chemotherapy when treating early-stage lung cancer patients. But instead, they discovered the most incredible benefit – disease-free survival – which will help people in their fight against the disease.

The results of the trial proved that Osimertinib provided an 89% two-year disease-free survival for resected lung cancer (stage IB/II/IIIA) patients compared to the 53% disease-free survival rate exhibited in patients on randomized treatment with placebo. In this trial, the patients on Osimertinib saw a 79% reduction in their risk of cancer recurrence or death. The team will keep monitoring patients to establish overall survival outcomes.

Osimertinib is an oral, third-generation epidermal growth factor receptor tyrosine-kinase inhibitor that shuts down the activity of certain genetic mutations that contribute to the development of non-small cell lung cancer in a subset of patients.

The drug was first approved in 2015 for patients with EGFR mutation-positive advanced lung cancer. Now, this treatment is approved worldwide for treating non-metastatic, non-small cell lung cancer in the same setting.

Participants in the trial had had surgery to remove lung tumors and also chemotherapy. The disease-free survival was consistent in those who used Osimertinib, even those who didn’t undergo chemotherapy.

Osimertinib is specifically targeted to EGFR mutations and helps patients to prevent the recurrence of several cancers, including brain, lung, and liver.

More Choice Cancer Care Centers